KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Inventory: 2010-2024

Historic Inventory for Emergent BioSolutions (EBS) over the last 15 years, with Dec 2024 value amounting to $311.7 million.

  • Emergent BioSolutions' Inventory rose 10.41% to $356.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $356.3 million, marking a year-over-year increase of 10.41%. This contributed to the annual value of $311.7 million for FY2024, which is 5.23% down from last year.
  • According to the latest figures from FY2024, Emergent BioSolutions' Inventory is $311.7 million, which was down 5.23% from $328.9 million recorded in FY2023.
  • Emergent BioSolutions' 5-year Inventory high stood at $350.7 million for FY2022, and its period low was $307.0 million during FY2020.
  • Moreover, its 3-year median value for Inventory was $328.9 million (2023), whereas its average is $330.4 million.
  • In the last 5 years, Emergent BioSolutions' Inventory surged by 37.98% in 2020 and then decreased by 6.22% in 2023.
  • Yearly analysis of 5 years shows Emergent BioSolutions' Inventory stood at $307.0 million in 2020, then climbed by 12.21% to $344.5 million in 2021, then climbed by 1.80% to $350.7 million in 2022, then decreased by 6.22% to $328.9 million in 2023, then dropped by 5.23% to $311.7 million in 2024.